Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLLNASDAQ:HUMANASDAQ:MLYSNASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$26.78+3.0%$28.46$23.23▼$42.29$860.50M0.76442,090 shs288,803 shsHUMAHumacyte$1.48+0.7%$2.41$1.15▼$9.97$229.58M1.623.56 million shs1.76 million shsMLYSMineralys Therapeutics$14.09+4.1%$12.84$8.24▼$18.38$914.10M-0.39421,724 shs394,554 shsNTLAIntellia Therapeutics$8.18+1.1%$8.73$5.90▼$28.18$846.77M2.232.37 million shs1.53 million shs20 Stocks to Sell NowGet This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+3.04%-0.85%-11.18%-17.83%-24.52%HUMAHumacyte+0.68%-11.90%-48.61%-67.90%-61.26%MLYSMineralys Therapeutics+4.14%+5.54%-16.03%+41.32%+24.03%NTLAIntellia Therapeutics+0.93%+13.14%-6.30%-25.57%-61.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.0932 of 5 stars3.42.00.03.02.70.82.5HUMAHumacyte2.2718 of 5 stars3.51.00.00.02.13.30.6MLYSMineralys Therapeutics2.6647 of 5 stars3.51.00.00.03.15.00.0NTLAIntellia Therapeutics4.5213 of 5 stars4.31.00.04.73.32.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.80Moderate Buy$43.6062.81% UpsideHUMAHumacyte 3.00Buy$13.71826.64% UpsideMLYSMineralys Therapeutics 3.00Buy$33.00134.21% UpsideNTLAIntellia Therapeutics 2.65Moderate Buy$36.68348.46% UpsideCurrent Analyst Ratings BreakdownLatest HUMA, COLL, MLYS, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025NTLAIntellia TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$21.004/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/2/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $42.003/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/24/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/10/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/7/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/5/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/4/2025NTLAIntellia TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$90.00 ➝ $50.002/28/2025NTLAIntellia TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $26.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.36$9.70 per share2.76$5.99 per share4.47HUMAHumacyte$1.57M146.23N/AN/A$0.13 per share11.38MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ANTLAIntellia Therapeutics$57.88M14.63N/AN/A$11.73 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$48.15M$1.8611.544.45N/A14.78%104.67%18.38%5/8/2025 (Estimated)HUMAHumacyte-$110.78M-$1.26N/AN/AN/AN/A-942.81%-93.82%5/9/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.64N/AN/AN/AN/A-67.97%-62.40%5/8/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.25N/AN/AN/AN/A-49.34%-40.27%5/8/2025 (Estimated)Latest HUMA, COLL, MLYS, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025HUMAHumacyte-$0.19N/AN/AN/A$0.46 millionN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50N/AN/AN/A$174.96 millionN/A5/8/2025Q1 2025MLYSMineralys Therapeutics-$1.02N/AN/AN/AN/AN/A5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26N/AN/AN/A$11.39 millionN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million2/27/2025Q4 2024COLLCollegium Pharmaceutical$1.54$1.63+$0.09$0.36$179.68 million$181.95 million2/12/2025Q4 2024MLYSMineralys Therapeutics-$1.00-$0.98+$0.02-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.430.970.88HUMAHumacyteN/A1.101.10MLYSMineralys TherapeuticsN/A14.0214.02NTLAIntellia TherapeuticsN/A6.736.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AHUMAHumacyte44.71%MLYSMineralys Therapeutics84.46%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%HUMAHumacyte11.20%MLYSMineralys Therapeutics33.24%NTLAIntellia Therapeutics3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million30.97 millionOptionableHUMAHumacyte150155.12 million111.76 millionOptionableMLYSMineralys Therapeutics2864.88 million33.27 millionOptionableNTLAIntellia Therapeutics600103.52 million98.59 millionOptionableHUMA, COLL, MLYS, and NTLA HeadlinesRecent News About These CompaniesBank of Montreal Can Purchases New Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 25 at 3:26 AM | marketbeat.comWells Fargo & Company MN Purchases 76,872 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 25 at 3:17 AM | marketbeat.comLawsuit for Investors in shares of Intellia Therapeutics, Inc. ...April 23 at 1:47 PM | gurufocus.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 10.1% - Still a Buy?April 23 at 12:58 PM | marketbeat.comLawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders FoundationApril 23 at 9:50 AM | prnewswire.comWolfe Research Upgrades Intellia Therapeutics (NASDAQ:NTLA) to OutperformApril 23 at 9:09 AM | marketbeat.comWolfe Research Upgrades Intellia Therapeutics (NTLA)April 22 at 6:10 AM | msn.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Rockefeller Capital Management L.P.April 22 at 3:48 AM | marketbeat.comRussell Investments Group Ltd. Has $1.37 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 22 at 3:19 AM | marketbeat.comIntellia Therapeutics upgraded at Wolfe on sentiment, valuationApril 21, 2025 | markets.businessinsider.comFederated Hermes Inc. Has $45,000 Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 21, 2025 | marketbeat.comGeode Capital Management LLC Increases Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 20, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Jump Financial LLCApril 19, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 4.9% - Should You Sell?April 18, 2025 | marketbeat.comBrokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Target Price at $37.56April 18, 2025 | americanbankingnews.comContrasting TNF Pharmaceuticals (NASDAQ:TNFA) and Intellia Therapeutics (NASDAQ:NTLA)April 17, 2025 | americanbankingnews.comAlliancebernstein L.P. Lowers Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 17, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 16, 2025 | marketbeat.comIntellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLAApril 15, 2025 | globenewswire.comFIL Ltd Grows Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)April 15, 2025 | marketbeat.comNTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc.April 15, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound Potential2 Healthcare Recession-Resistant Stocks Unaffected by TariffsBy Jea Yu | April 15, 2025View 2 Healthcare Recession-Resistant Stocks Unaffected by TariffsHUMA, COLL, MLYS, and NTLA Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$26.78 +0.79 (+3.04%) As of 04/24/2025 04:00 PM EasternCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Humacyte NASDAQ:HUMA$1.48 +0.01 (+0.68%) As of 04/24/2025 04:00 PM EasternHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Mineralys Therapeutics NASDAQ:MLYS$14.09 +0.56 (+4.14%) As of 04/24/2025 04:00 PM EasternMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Intellia Therapeutics NASDAQ:NTLA$8.18 +0.09 (+1.11%) As of 04/24/2025 04:00 PM EasternIntellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
